PDF-HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include a

Limitation of Use Should only be used for acute treatment periods up to two or three weeks 1DOSAGE AND ADMINISTRATION DESCRIPTIONCLINCIAL PHARMACOLOGY121. See full prescribing information for BIOTHRAX BIOTHRAX Anthrax Vaccine Adsorbed Suspension for Intramuscular or Subcutaneous Injection Initial US Approval 1970 RECENT MAJOR CHANGES DOSAGE AND ADMINISTRATION 21 May2012 INDICATIONS AND USAGE Bacillu See full prescribing information for Ferric Citrate Ferric Citrate ablet containing 210 mg of ferric iron equivalent to 1 g ferric citrate for ral se Initial U Approval 2014 INDICATIONS AND USAGE Ferric Citrate s a phosphate binder indicated for See full prescribing information for LATISSE LATISSE bimatoprost ophthalmic solution 003 Initial US Approval 2001 INDICATIONS AND USAGE LATISSE is a prostaglandin analog indicated to treat hypotrichosis of the eyelashes by increasing their growth --------------------------RECENT MAJOR CHANGES---------------------------- Boxed Warning 04/15 Indications and Usage (1.1) 04/15 Dosage and Administration (2.1, 2.2) 04/15 Warnings a NDA 22-288/S-003 Reference ID: 3151309 NDA 22-288/S-003 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is a histamine H receptor antagoni Anthony Oxley – Head of Pharmacy. The Driver for Implementing EPMA?. Mental Health, Learning Disability and Community Health Services.. Prince2 Project . JAC User. Leicestershire Partnership NHS Trust. Senior Lecturer . Leeds Beckett University . Miranda Thew. Aims. Public health agenda . Understanding Social Prescribing. A Role less travelled! . Exploring ideas for an occupational therapist role. . Outline. Antibiotic prescribing across the U.S.. What is known about antibiotic prescribing in New York State. CDC’s Get Smart program. Our antibiotic prescribing project. Resources. Slide from CDC Get Smart Program. 5.1Hypersensitivity5.2Exogenous Ochronosis5.3Effects on Endocrine System5.4Cutaneous ReactionsADVERSE REACTIONSUSE IN SPECIFIC POPULATIONS8.1Pregnancy8.3NursingMothers8.4Pediatric Use8.5Geriatric Use1 WARNING: LOSS OF BONE MINERAL DENSITY Women who use Depo-Provera Contraceptive Injection may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be Reference ID 3406989FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE luliconazole Cream 1 is indicated for the topical treatment of interdigital tinea pedis tinea cruris and tinea corporis caused b treatment and adjust dosing as needed 22 51 constipation nausea and vomiting as needed 22 52 Peripheral Neuropathy Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed 2 VITROL naltrexone for extendedrelease injectable suspension for intramuscular useInitial US ApprovalRECENT MAJOR CHANGESDosage and Administration 22 03/2021Warnings and Precautions 51 03/2021INDICATIO WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of BOTOXand all botulinum toxin products may spread from the area of injection to produ